Merck KGaA’s Oncology Sales And Pipeline Updates Dominate Q3 Earnings
Bavencio Sees Double-Digit Growth
The German firm’s oncology franchise grew to more than €400m in the third quarter as sales of Bavencio doubled, while anticancer partnerships and pipeline updates drew interest.
You may also be interested in...
The German group says that 50% of future new launches are expected to come from externally sourced assets to take the strain of its organic discovery engine.
The UK firm’s obe-cel has met the primary endpoint in a Phase II acute lymphocytic leukemia trial, triggering filing plans and a $150m public offering as observers commend the drug’s competitive safety profile.
Recent executive changes in the industry include C-suite changes at Solid Biosciences and Merck & Co. Meanwhile, new directors were appointed at Allergy Therapeutics and Synairgen.